Hematopoietic cell transplantation in patients with primary immune regulatory disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) survey Journal Article


Authors: Chan, A. Y.; Leiding, J. W.; Liu, X.; Logan, B. R.; Burroughs, L. M.; Allenspach, E. J.; Skoda-Smith, S.; Uzel, G.; Notarangelo, L. D.; Slatter, M.; Gennery, A. R.; Smith, A. R.; Pai, S. Y.; Jordan, M. B.; Marsh, R. A.; Cowan, M. J.; Dvorak, C. C.; Craddock, J. A.; Prockop, S. E.; Chandrakasan, S.; Kapoor, N.; Buckley, R. H.; Parikh, S.; Chellapandian, D.; Oshrine, B. R.; Bednarski, J. J.; Cooper, M. A.; Shenoy, S.; Davila Saldana, B. J.; Forbes, L. R.; Martinez, C.; Haddad, E.; Shyr, D. C.; Chen, K.; Sullivan, K. E.; Heimall, J.; Wright, N.; Bhatia, M.; Cuvelier, G. D. E.; Goldman, F. D.; Meyts, I.; Miller, H. K.; Seidel, M. G.; Vander Lugt, M. T.; Bacchetta, R.; Weinacht, K. G.; Andolina, J. R.; Caywood, E.; Chong, H.; de la Morena, M. T.; Aquino, V. M.; Shereck, E.; Walter, J. E.; Dorsey, M. J.; Seroogy, C. M.; Griffith, L. M.; Kohn, D. B.; Puck, J. M.; Pulsipher, M. A.; Torgerson, T. R.
Article Title: Hematopoietic cell transplantation in patients with primary immune regulatory disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) survey
Abstract: Primary Immune Regulatory Disorders (PIRD) are an expanding group of diseases caused by gene defects in several different immune pathways, such as regulatory T cell function. Patients with PIRD develop clinical manifestations associated with diminished and exaggerated immune responses. Management of these patients is complicated; oftentimes immunosuppressive therapies are insufficient, and patients may require hematopoietic cell transplant (HCT) for treatment. Analysis of HCT data in PIRD patients have previously focused on a single gene defect. This study surveyed transplanted patients with a phenotypic clinical picture consistent with PIRD treated in 33 Primary Immune Deficiency Treatment Consortium centers and European centers. Our data showed that PIRD patients often had immunodeficient and autoimmune features affecting multiple organ systems. Transplantation resulted in resolution of disease manifestations in more than half of the patients with an overall 5-years survival of 67%. This study, the first to encompass disorders across the PIRD spectrum, highlights the need for further research in PIRD management.
Keywords: genetics; autoimmunity; immune dysregulation; hematopoietic cell transplant; primary immune deficiencies
Journal Title: Frontiers in Immunology
Volume: 11
ISSN: 1664-3224
Publisher: Frontiers Media S.A.  
Date Published: 2020-02-21
Start Page: 239
Language: English
DOI: 10.3389/fimmu.2020.00239
PROVIDER: scopus
PMCID: PMC7046837
PUBMED: 32153572
DOI/URL:
Notes: Article -- Export Date: 1 April 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Susan E Prockop
    262 Prockop